Wells Fargo & Co upgraded shares of Gilead Sciences (NASDAQ:GILD) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage currently has $96.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $79.02.

GILD has been the topic of a number of other research reports. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a hold rating in a report on Wednesday, January 3rd. Oppenheimer assumed coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They set a market perform rating on the stock. Mizuho increased their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a buy rating in a report on Wednesday, November 8th. Leerink Swann increased their price objective on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a market perform rating in a report on Thursday, October 5th. Finally, BMO Capital Markets decreased their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an outperform rating on the stock in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $85.53.

Gilead Sciences (NASDAQ GILD) traded down $0.19 on Tuesday, hitting $80.98. 7,920,878 shares of the stock traded hands, compared to its average volume of 8,120,000. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a market cap of $105,750.00, a price-to-earnings ratio of 9.21, a price-to-earnings-growth ratio of -1.77 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences will post 8.48 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

In related news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 591,666 shares of company stock worth $44,466,567 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in GILD. Welch Investments LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management raised its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the period. Institutional investors and hedge funds own 75.95% of the company’s stock.

WARNING: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2018/01/19/gilead-sciences-gild-rating-increased-to-outperform-at-wells-fargo-co.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.